BR112012000750B1 - sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo - Google Patents

sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo Download PDF

Info

Publication number
BR112012000750B1
BR112012000750B1 BR112012000750-5A BR112012000750A BR112012000750B1 BR 112012000750 B1 BR112012000750 B1 BR 112012000750B1 BR 112012000750 A BR112012000750 A BR 112012000750A BR 112012000750 B1 BR112012000750 B1 BR 112012000750B1
Authority
BR
Brazil
Prior art keywords
salt
shows
ray diffraction
fact
citrate salt
Prior art date
Application number
BR112012000750-5A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112012000750A2 (pt
BR112012000750A8 (pt
Inventor
Bryan Dymock
Cheng Hsia Angeline Lee
Anthony Deodaunia William
Original Assignee
Cti Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cti Biopharma Corp. filed Critical Cti Biopharma Corp.
Publication of BR112012000750A2 publication Critical patent/BR112012000750A2/pt
Publication of BR112012000750A8 publication Critical patent/BR112012000750A8/pt
Publication of BR112012000750B1 publication Critical patent/BR112012000750B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112012000750-5A 2009-07-15 2010-07-14 sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo BR112012000750B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22560909P 2009-07-15 2009-07-15
US61/225609 2009-07-15
PCT/SG2010/000265 WO2011008172A1 (en) 2009-07-15 2010-07-14 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Publications (3)

Publication Number Publication Date
BR112012000750A2 BR112012000750A2 (pt) 2016-08-09
BR112012000750A8 BR112012000750A8 (pt) 2018-02-06
BR112012000750B1 true BR112012000750B1 (pt) 2021-05-25

Family

ID=42790728

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000750-5A BR112012000750B1 (pt) 2009-07-15 2010-07-14 sal citrato cristalino, composição farmacêutica compreendendo o referido sal e uso do mesmo

Country Status (18)

Country Link
US (1) US9062074B2 (enExample)
EP (1) EP2454266B1 (enExample)
JP (2) JP6013911B2 (enExample)
CN (1) CN102762577B (enExample)
AR (2) AR077483A1 (enExample)
BR (1) BR112012000750B1 (enExample)
CA (1) CA2768210C (enExample)
DK (1) DK2454266T3 (enExample)
ES (1) ES2429525T3 (enExample)
HR (1) HRP20130941T1 (enExample)
MX (1) MX2012000680A (enExample)
PL (1) PL2454266T3 (enExample)
PT (1) PT2454266E (enExample)
RU (1) RU2543721C2 (enExample)
SI (1) SI2454266T1 (enExample)
SM (1) SMT201300112B (enExample)
TW (1) TWI537276B (enExample)
WO (1) WO2011008172A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
HK1255104A1 (zh) 2015-12-15 2019-08-02 Context Biopharma Inc. 无定形的奥那司酮组合物及其制备方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US7151096B2 (en) 2003-03-05 2006-12-19 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
CN101360751B (zh) * 2005-11-16 2011-09-14 S*Bio私人有限公司 氧连接的嘧啶衍生物

Also Published As

Publication number Publication date
ES2429525T3 (es) 2013-11-15
HRP20130941T1 (hr) 2013-11-08
BR112012000750A2 (pt) 2016-08-09
PT2454266E (pt) 2013-10-10
DK2454266T3 (da) 2013-09-08
PL2454266T3 (pl) 2014-01-31
EP2454266B1 (en) 2013-07-10
BR112012000750A8 (pt) 2018-02-06
RU2543721C2 (ru) 2015-03-10
HK1178159A1 (en) 2013-09-06
MX2012000680A (es) 2012-02-28
CA2768210A1 (en) 2011-01-20
US20120196876A1 (en) 2012-08-02
AR077483A1 (es) 2011-08-31
WO2011008172A1 (en) 2011-01-20
JP6013911B2 (ja) 2016-10-25
EP2454266A1 (en) 2012-05-23
CA2768210C (en) 2017-08-15
TW201107336A (en) 2011-03-01
SI2454266T1 (sl) 2013-10-30
SMT201300112B (it) 2013-11-08
AR114987A2 (es) 2020-11-11
JP2015164941A (ja) 2015-09-17
CN102762577A (zh) 2012-10-31
US9062074B2 (en) 2015-06-23
JP2012533539A (ja) 2012-12-27
TWI537276B (zh) 2016-06-11
CN102762577B (zh) 2015-01-07
RU2012105044A (ru) 2013-08-20

Similar Documents

Publication Publication Date Title
US12448366B2 (en) Solid forms of pralsetinib
TWI537276B (zh) ９ｅ－１５－（２－吡咯啶－１－基－乙氧基）－７，１２，２５－三－１９，２１，２４－三氮雜－四環〔１８．３．１．１（２，５）．１（１４，１８）〕二十六碳－１（２４），２，４，９，１４，１６，１８（２６），２０，２２－壬烯檸檬酸鹽
TWI449705B (zh) １１－（２－吡咯啶－１－基－乙氧基）－１４，１９－二－５，７，２６－三氮雜－四環〔１９．３．１．１（２，６）．１（８，１２）〕二十七碳－１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３－十烯檸檬酸鹽
ES2536276T3 (es) Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno
EP3283483B1 (en) Crystalline eliglustat hydrochloride
KR20200071090A (ko) 에다라본 염
WO2022171117A1 (zh) 含氮稠杂环化合物的盐、晶型及其制备方法、药物组合物和用途
US20260109685A1 (en) Solid forms of pralsetinib
AU2022234309B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
ES2989906T3 (es) Diferentes formas de 6-cloro-2-etil-N-(4-(4-(4-(trifluorometoxi)fenil)piperidin-1-il)bencil)imidazo[1,2-a]piridin-3-carboxamida
US20260055058A1 (en) Psilocin crystalline forms
TW202602859A (zh) 製備基本上不含亞硝胺雜質的瑞布替尼之方法
HK40095644A (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: S*BIO PTE LTDA (SG)

B25A Requested transfer of rights approved

Owner name: CELL THERAPEUTICS, INC. (US)

B25D Requested change of name of applicant approved

Owner name: CTI BIOPHARMA CORP. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/07/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.